Aevitas Wealth Management, Inc. Biogen Inc. Transaction History

Aevitas Wealth Management, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 19, 2021	SELL	$236.26 - $355.63 $182,156 - $274,190	-771 Closed	0 $0
Q2 2020 Jul 29, 2020	BUY	$258.66 - $342.55 $4,138 - $5,480	16 Added 2.12%	771 $206,000
Q4 2019 Jan 31, 2020	SELL	$220.06 - $304.07 $120,372 - $166,326	-547 Reduced 42.01%	755 $224,000
Q3 2019 Oct 21, 2019	SELL	$217.44 - $243.88 $56,534 - $63,408	-260 Reduced 16.65%	1,302 $303,000
Q2 2019 Jul 26, 2019	SELL	$219.29 - $241.72 $193,633 - $213,438	-883 Reduced 36.11%	1,562 $365,000
Q1 2019 May 09, 2019	BUY	$216.71 - $338.96 $75,848 - $118,636	350 Added 16.71%	2,445 $577,000
Q4 2018 Feb 14, 2019	BUY	$278.5 - $352.75 $4,177 - $5,291	15 Added 0.72%	2,095 $630,000
Q3 2018 Nov 14, 2018	BUY	$293.51 - $383.83 $14,675 - $19,191	50 Added 2.46%	2,080 $735,000
Q2 2018 Aug 10, 2018	BUY	$257.52 - $306.91 $41,203 - $49,105	160 Added 8.56%	2,030 $589,000
Q1 2018 May 15, 2018	SELL	$260.13 - $367.91 $52,026 - $73,582	-200 Reduced 9.66%	1,870 $512,000
Q4 2017 Feb 13, 2018	BUY	$307.64 - $344.58 $636,814 - $713,280	2,070	2,070 $659,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Aevitas Wealth Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Aevitas Wealth Management, Inc. with notifications on news.